Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22539971 | 0.85 | FAAH (0.58) | FAAHCASP2NAAAEPHX1 | |
| SCHEMBL16276160 | 0.83 | FAAH (0.39) | FAAHKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL13411276 | 0.82 | FAAH (0.47) | FAAHKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL18057043 | 0.81 | FAAH (0.49) | FAAHKDM4EMAPK1HIF1ASMN1; SMN2 | |
| SCHEMBL12600744 | 0.78 | — | — | |
| SCHEMBL15075515 | 0.78 | FAAH (0.56) | FAAHMEN1KMT2ACES2CASP2 | |
| SCHEMBL15773187 | 0.75 | CYP2C19 (0.38) | FAAHSMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL13411277 | 0.75 | TSHR (0.59) | FAAHKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL21388218 | 0.73 | ALDH1A1 (0.41) | KDM4ESMN1; SMN2ALDH1A1NAMPTLMNA | |
| SCHEMBL27986572 | 0.73 | FAAH (0.70) | FAAHMEN1KMT2ACASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | CCR5, OPRM1, OPRK1 | FAAH 1711/4885KDM4E 4113/4885MAPK1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.